Improving biopharma R&D lifecycle management with biopharma 4.0
This report explores why implementing a biopharma 4.0 approach is necessary for achieving higher flexibility, efficiency and robustness in the lifecycle of a drug
Add bookmark
The rapid development and global rollout of Covid-19 vaccines provides the ultimate case study of how the biopharma 4.0 approach was utilized to transform pharmaceutical R&D. While digital R&D solutions played a pivotal role in pharma’s speedy response to the pandemic, new therapeutic drugs can also be brought to market safely and efficiently via a digitized, flexible and robust lifecycle.
In this report, Pharma IQ – in collaboration with IDBS – analyzes how to meet the challenges of digitizing pharma’s R&D practices and explores examples of how pharma companies have utilized biopharma 4.0 to accelerate their product’s speed-to-market.
Download this report to learn:
- Why a biopharma 4.0 approach can provide an end-to-end solution market advantage in R&D
- Which solutions can assist in overcoming data management challenges during drug development
- How the biopharma lifecycle can be navigated using IDBS’s Polar management platform
Sponsored By:
